Hayo Therapeutics SASwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Tag Archive for: Roche
Innerstream - wikimedia.orgRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis
Sangamo Therapeutics IncAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
Adaütimmune LtdThe US Food & Drug Administration has granted accelerated approval to Adaptimmune’s Tecelra as the world’s first therapy with genetically engineered T cells to fight a solid tumour.
At the end of May, Dr Uwe Meya took over as Chief Medical Officer at Oxford-based SynaptixBio.
Roche, Herzog&De MeuronObesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.
Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich.
Multi-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection platform.
Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.